arrow
M

Murat Terzi

ondokuz mayis university
H指数:38
被引数:7,148

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dimethyl fumarate in the treatment of multiple sclerosis: real-world effectiveness in a Turkish cohort

富马酸二甲酯在多发性硬化症治疗中的真实世界有效性:土耳其队列研究

2026-11-130
OA
Exploring the Type 4 Cerebrospinal Fluid Oligoclonal Band Pattern: Clinical and Paraclinical Features with Diagnostic Implications

探讨脑脊液寡克隆带类型4模式:具有诊断意义的临床及辅助临床特征

2026-09-090
PRE
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

在复发缓解型多发性硬化中,针对临床静息期MRI病灶的治疗升级

Brain
IF11.7
2026-07-240
OAAI
Causal effects of multiple sclerosis therapies in left-truncated registry data

多发性硬化疗法在左截断登记数据中的因果效应

2026-07-210
PRE
Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder

真实世界中eculizumab在AQP4-IgG阳性视神经脊髓炎谱系障碍中的有效性和安全性

2026-01-080
OAAI
Real-World Effectiveness of Ocrelizumab in Relapsing Multiple Sclerosis: an MSBase Registry Sub-Study

奥法美南在复发型多发性硬化中的真实世界有效性:一项MSBase登记研究的子研究

2025-11-250
OAAI
The relationships between perceived social support, psychological well-being and acceptance-rejection levels toward their children in parents with multiple sclerosis: A conditional process model

多发性硬化症患者父母感知的社会支持、心理幸福感与其对子女的接纳-拒绝水平之间的关系:一项条件过程模型研究

2025-09-260
PRE
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE
Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study

克立屈滨在因转氨酶水平升高而停用芬戈莫德的患者中的安全性与有效性:FinClad研究

2025-06-100
PRE
Exome sequencing reveals low-frequency and rare variant contributions to multiple sclerosis susceptibility in Turkish families
2025-04-050
OAAI
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

一年治疗反应预测复发缓解型多发性硬化患者后续5年的疾病进程

2025-02-010
OAAI